Breaking AI & Tech News Analyzed

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

A federal judge in Miami has dismissed former President Donald Trump’s defamation lawsuit against the Wall Street Journal and News Corp, granting the former president a two‑week deadline to refile the case. Trump’s suit, filed last summer, alleged that a lewd drawing featured in a July 2025 article—purportedly a “bawdy” birthday letter to the late financier Jeffrey Epstein—was fabricated, and that the newspaper published it with actual malice. The complaint also named media mogul Rupert Murdoch, whose News Corp owns the Journal, as a defendant. Judge Darrin P. Gayles ruled that the complaint “fails to adequately allege actual malice,” the legal standard required for defamation actions by public figures. He noted that the Journal had conducted a “significant” inquiry into the authenticity of the drawing and that Trump’s assertion of falsity alone does not prove the newspaper acted with “serious doubts” about the story’s truth. In his opinion, the judge wrote: “Because President Trump has not plausibly alleged that defendants published the article with actual malice, both counts must be dismissed.” He also observed that Trump’s team had not presented evidence of special damages. Under the order, Trump may refile the lawsuit by April 27 with additional proof that the Journal knowingly published false material. A spokesperson for Trump’s legal team confirmed they will pursue a revised filing, emphasizing the administration’s intent to “hold accountable those who traffic in fake news.” The Wall Street Journal and its parent company, Dow Jones, welcomed the decision. A Dow Jones representative said, “We stand behind the reliability, rigor and accuracy of The Wall Street Journal’s reporting.” The dismissal underscores the stringent “actual malice” requirement for defamation suits involving public officials, a threshold that continues to shape media‑law battles in the United States. It also leaves Trump with ongoing litigation against the BBC and other media outlets over separate First Amendment disputes.

Plans to alter the size of HS2 trains, aimed at maximizing capacity, may result in increased costs and fewer seats, potentially leading to slower services north of Birmingham. A senior government and rail industry figure, Chris Gibb, has warned against changing the train order.The original £2bn order for 54 high-speed trains, to be built by a joint venture of Alstom and Hitachi, was placed in 2021. However, the project has been under review since the cancellation of the northern leg of HS2 by Rishi Sunak in 2023. The initial plan was for the 200-metre, eight-carriage units to double into 16-carriage trains, similar in size to a Eurostar. But this will only be feasible on the new line between London and Birmingham, as existing stations like Manchester Piccadilly cannot accommodate a 400-metre train.Gibb, a non-executive director of DfT Operator, expressed concerns that if HS2 opens with eight-coach trains, they would be full, leaving people behind. He suggested that instead of varying the train order, which could incur extra costs and delays, the government should retain the original order and plan to replace the current Pendolino fleet with longer, faster, modern versions around 2040.This approach, Gibb argued, would provide a significant increase in capacity, revenue, and a reduction in journey times on all routes without the need for further railway construction. Lord McLoughlin, former transport secretary, and Lord Berkeley, a long-term HS2 sceptic, have backed Gibb's idea, emphasizing the importance of consistent rolling stock for future use.A spokesperson for HS2 Ltd stated that no changes have been made to the original order, and they are still working closely with the manufacturer and the DfT to finalize train designs. The trains will be built in Derby and Newton Aycliffe.

Goldman Sachs's chief executive, David Solomon, has expressed heightened awareness of the capabilities of Anthropic's Mythos AI model and is collaborating closely with the tech firm following warnings about the cybersecurity risk it poses.The US bank has been closely monitoring the rapid advancements in artificial intelligence, including large language models (LLMs), as part of broader efforts to protect itself from hackers.“Obviously the LLMs are making rapid progress and we’re hyper-aware of the enhanced capabilities of these new models with the help of the US government and the model publishers,” Solomon told analysts on an earnings call on Monday.Anthropic, the company behind the Claude family of AI tools, claimed last week that its latest model, Mythos, posed an unprecedented risk due to its ability to expose flaws in IT systems. The company warned that AI models have reached a level of coding capability where they can surpass all but the most skilled humans at finding and exploiting software vulnerabilities.Solomon emphasized that Goldman Sachs is working closely with Anthropic and all of its security vendors to harness frontier capabilities. “We are very focused on supplementing our cyber and infrastructure resilience. And this is part of our ongoing capabilities that we have been investing in, and are accelerating our investment in.”The news comes after the US Treasury secretary, Scott Bessent, summoned Solomon and other big American bankers to Washington to discuss the Mythos model last week. The meeting focused on heads of so-called systemically important banks, where regulators believe that a major disruption to their operations, or their potential collapse, would put financial stability at risk.On Monday, the UK government’s AI Security Institute (AISI) warned that Mythos was a “step up” over previous models in terms of the cyber threat it posed. AISI said Mythos could carry out attacks that required multiple actions and discover weaknesses in IT systems without human intervention.

Meta, the company behind Facebook and Instagram, is reportedly working on an AI version of its CEO, Mark Zuckerberg. This AI clone is being trained on Zuckerberg's mannerisms, tone, and public statements to allow employees to interact with a digital version of their boss.The rationale behind this project is to make Meta's 79,000 employees feel more connected to one of the most influential figures in Silicon Valley. The AI character will be developed using images and the voice of Zuckerberg, with the CEO reportedly taking part in the training process.This move is part of Meta's broader effort to integrate AI into its business operations. The company aims to use AI to lower costs and accelerate work pace. Zuckerberg has emphasized the importance of efficiency, stating that the goal is to 'get more done' by elevating individual contributors and flattening teams.The development of this AI character follows Meta's previous experiments with digital avatars. In 2022, Zuckerberg shared his own avatar in the metaverse, which received public criticism for its graphic quality. The company has since scaled back its metaverse vision, focusing on AI-generated 3D characters for everyday conversations.Meta's investment in AI is part of a larger strategy to remain competitive with tech rivals. The company is pouring billions of dollars into AI research to create 'superintelligence,' a system capable of performing any cognitive task far better than a human.

Justin Rose secured a joint‑third place at the 2026 Masters, ending the tournament two shots behind defending champion Rory McIlroy. The result marked Rose’s third top‑six finish in his last eight major appearances. After a heartbreaking playoff loss to McIlroy at Augusta in 2025, Rose entered Sunday’s final round with the lead on the back‑nine but ultimately carded a final‑round 70 following a stumble at the famed Amen Corner. Reflecting on his performance, Rose said, "In the last two years I’ve really re‑kicked and re‑energised my career. I now have a lot of belief that there’s plenty of runway ahead." The 45‑year‑old, who claimed a PGA Tour victory in February, believes his recent form positions him to compete for future major titles. Rose emphasized that the majors are the events that drive his preparation: "These are the tournaments I focus on, the ones that make me put in that extra mile to show up and stay in these great arenas." His record at Augusta is notable, with eight top‑10 finishes and two runner‑up finishes, underscoring his affinity for the course. Rose cited veterans such as Freddie Couples and Bernhard Langer as inspirations, noting that the layout of Augusta rewards deep course knowledge and a personal playing style. Englishman Tyrrell Hatton also made headlines, posting a spectacular final‑round 66 that included six birdies and an eagle, propelling him to a joint‑third finish – his best performance in a major to date. Hatton explained his approach: "I try not to treat majors any differently – I go out every day, every round, every shot, and give it my best. I’m looking at ways to fine‑tune my preparation, perhaps more putting early in the week, to feel even more ready." Now in his tenth Masters, Hatton highlighted his steady improvement, citing recent top‑10 finishes at the U.S. Open and a rise from a tied‑fourteenth to a tied‑ninth in the last three years at Augusta.

Taiwan's 'Sunshine Women's Choir' has taken the local box office by storm, but its success has been met with criticism over its emotionally manipulative tactics and lack of depth. The film, adapted from the 2010 Korean movie 'Harmony,' tells the story of Hui-Zhen, a woman who forms a choir with her fellow inmates to raise her infant daughter behind bars.The movie's director, Gavin Lin, has been accused of resorting to manipulative tactics to elicit emotions from the audience, including excessive crying and contrived plot twists. Despite its feel-good/feel-bad tone, the film's relentlessly peppy approach undermines any potential for foundational grit, critics argue.The story follows Hui-Zhen's journey as she navigates life in prison and forms a choir with her fellow inmates. However, the film's sanitized portrayal of prison life and its lack of meaningful character development have been criticized. The movie's use of showstoppers and flashbacks has also been seen as a way to avoid addressing the characters' deeper issues.Despite its criticisms, 'Sunshine Women's Choir' is set to hit UK cinemas on April 17. The film's success has sparked a debate about the role of emotion in filmmaking and the importance of depth in storytelling.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

History’s Greatest Fails pairs author Elizabeth Day with historian Dan Jones to explore celebrated historical missteps. After a witty reunion anecdote about their Cambridge days, the duo tackles the myth of Richard III’s villainy and promises a future episode on Henry VIII and Anne Boleyn, dubbed the "Ross and Rachel of early modern history."Strangely follows presenters Poppy Damon and Luke Jones as they plunge into off‑beat news stories, such as the macabre tale of a surgeon who amputated his own legs and the obscure origin of Neil Hopper’s "eunuch‑maker" moniker. The show balances factual depth with a tongue‑in‑cheek tone.Passenger Seat is a slow‑burn true‑crime podcast produced by Pennsylvania writer Tom Joudrey. The inaugural season recounts the 2012 kidnapping of Jennifer Hurst in Ohio, unraveling the puzzling motive behind the crime and the surprising gratitude she later expressed in court.Big Bro With Kid Cudi marks rapper Kid Cudi’s entry into the "celebrity podcast industrial complex". His first interview features Kylie Jenner, who drops the usual Kardashian PR veneer to discuss family dynamics, her upcoming acting role in the film The Moment, and a brief nod to Timothée Chalamet.Northern News reunites comedian Amy Gledhill with Ian Smith to spotlight odd and delightful headlines from the north of England that often slip under the radar. Regular contributors such as Stevie Martin, Alison Spittle and Phil Wang add extra comic flair.